P08.46 Rechallenge with bevacizumab in a long-term survivor with glioblastoma

The prognosis of patients with glioblastoma multiforme (GBM, WHO grade IV), the most common primary brain tumor in adults, is generally poor with median survival of less than one year in untreated patients and approximately 15 months following standard of care therapy. However, 10 % survival at 5 years was observed in a randomized phase III study. At GBM recurrence, the addition of bevacizumab (BEV), a humanized monoclonal antibody against circulating vascular endothelial growth factor (VEGF), resulted in a 3–4 month prolongation of progression-free survival (PFS) without improving overall survival (OS). A 45-year-old female who underwent surgery for left fronto-temporal WHO grade II astrocytoma associated with epilepsy in 2005, 125I seed implantation at disease progression in 2009 and seed explantation 9 months later, was diagnosed with MGMT methylated GBM on the occasion of partial tumor resection in 2010 followed by radiotherapy plus concomitant and adjuvant temozolomide (TMZ) chemotherapy, which was stopped after 4 months due to resection of a left temporal tumor cyst and recurrent cyst within 1 month. TMZ treatment causing prolonged thrombocytopenia was discontinued after 1 additional cycle. Immediately after this cycle, the patient experienced left median cerebral artery stroke resulting in right hemianopia, Broca’s aphasia and severe hemiparesis of the right side. Three months later, BEV 10 mg/kg i.v. q14d was initiated, s...
Source: Neuro-Oncology - Category: Cancer & Oncology Authors: Tags: P08 Glioblastom and Anaplastic gliomas Source Type: research